Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia

- A case of extensively drug-resistant Acinetobacter baumannii bacteremia in an immunocompetent infant is reported.
- Tigecycline was used successfully with monitoring of trough serum concentrations to address its safety, efficacy, and pharmacokinetics.
- This is the first report of tigecycline monitoring in a pediatric patient with bloodstream infection​, and it is worth monitoring drug concentrations.
- This is the youngest case treated with tigecycline for A. baumannii bacteremia according to the published literature.
- Tigecycline can be given for life-threatening infections in children for whom no better alternative antimicrobial options are available.

SummaryThe successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented. Tigecycline serum concentrations were monitored to help improve antibiotic efficacy and minimize side effects. A literature review identified 11 additional pediatric cases of A. baumannii infection treated with tigecycline since 2011. Tigecycline treatment should be considered in children with extensively drug-resistant bacterial infections.